2025 at a glance

Acquisitions and licencing to enhance portfolio of treatments.
Included the acquisition of Akero Therapeutics, Inc. and its phase 3 asset (MASH) and licence agreements with The United Laboratories (triple receptor agonist) and Septerna, Inc. (small molecules).

Maziar Mike Doustdar appointed as president and chief executive officer of Novo Nordisk.
Maziar Mike Doustdar, formerly executive vice president of International Operations, succeeded Lars Fruergaard Jørgensen in the role.

Wegovy^® approved in the US for the treatment of MASH.
The Food and Drug Administration (FDA) approval positioned Wegovy^® as the first and only GLP-1 treatment approved for MASH, complementing proven weight loss and cardiovascular benefits.

Company-wide transformation plan to streamline operations and reinvest for growth.
Included a global workforce reduction of around 9,000 positions with annualised savings of DKK 8 billion from 2026 and onwards redirected to obesity and diabetes growth opportunities.

Expanded affordability options to bring our GLP-1s to more Americans.
Expanding access and affordability for our semaglutide medicines on top of existing initiatives such as lower self-pay prices and collaborations with select telehealth providers.

Advanced pipeline programmes and submitted new medicines for approval.
Key progress included advancing zenagamtide (amycretin) to initiate phase 3 trials in 2026, and filing weight management medicine CagriSema to the FDA.

FDA approval and launch of Wegovy^® pill in the US.
First and only approved once-daily oral GLP-1 medicine for weight management. With efficacy on par with injectable semaglutide and more optionality, this advancement opens new possibilities for the more than 100 million people living with obesity in the US.